Merck & Co., Inc. $MRK Stock Position Lifted by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 33.7% during the first quarter, Holdings Channel.com reports. The firm owned 31,032 shares of the company’s stock after acquiring an additional 7,830 shares during the period. EverSource Wealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $3,733,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Brighton Jones LLC raised its position in shares of Merck & Co., Inc. by 29.5% during the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after buying an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Merck & Co., Inc. by 52.2% in the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after acquiring an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC increased its stake in shares of Merck & Co., Inc. by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after acquiring an additional 15,636 shares during the period. Diversify Wealth Management LLC raised its holdings in Merck & Co., Inc. by 22.2% during the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after purchasing an additional 6,897 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Merck & Co., Inc. by 111.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock worth $53,918,000 after purchasing an additional 359,356 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Barclays raised its price target to $150 from $140 and maintained an “overweight” rating, implying roughly 15% upside from the referenced price. The increase reflects continued confidence in Merck’s outlook. Barclays raises Merck price target
• Positive Sentiment: KEYTRUDA met its primary progression-free-survival endpoint in a Phase 3 trial for advanced or recurrent endometrial cancer, outperforming platinum-based chemotherapy. Merck said the result could support future regulatory filings and strengthen its oncology pipeline. Merck KEYTRUDA endometrial cancer trial
• Positive Sentiment: Merck announced its fourth-quarter 2026 dividend, reinforcing the stock’s appeal to income-oriented investors and signaling continued capital-return support. The provided announcement did not include the dividend amount or payment details. Merck fourth-quarter dividend announcement
• Neutral Sentiment: Wells Fargo reiterated its Buy rating, while broader brokerage coverage places Merck at a “Moderate Buy” consensus, indicating generally favorable but not universally bullish sentiment. Wells Fargo maintains Merck Buy rating
• Negative Sentiment: Analysts expect Merck’s second-quarter earnings to decline, and a Zacks preview says the company lacks the typical signals associated with a likely earnings beat. This raises near-term execution risk ahead of the earnings report. Merck second-quarter earnings preview

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. CICC Research initiated coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target for the company. Scotiabank raised their target price on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research note on Tuesday, June 30th. Morgan Stanley lifted their target price on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Finally, Guggenheim upped their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a report on Monday, July 13th. Thirteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $134.50.

Merck & Co., Inc. Price Performance

NYSE MRK opened at $130.45 on Thursday. Merck & Co., Inc. has a 1 year low of $77.53 and a 1 year high of $135.05. The business’s fifty day moving average is $122.73 and its two-hundred day moving average is $118.24. The stock has a market capitalization of $322.18 billion, a P/E ratio of 36.75, a P/E/G ratio of 5.23 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same period last year, the company posted $2.22 EPS. The company’s revenue was up 4.9% compared to the same quarter last year. On average, research analysts forecast that Merck & Co., Inc. will post 2.74 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.6%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.